u/clara_danquah

The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.

Careful — you are treating retention time as identity. Two things can co-elute and the trace will not tell you.

Did you run a blank between injections?

Correcting myself upthread: I said the gradient was linear and looking again it has a hold in the middle.

a shoulder is not an impurity until you can resolve it

a COA is a certificate of analysis, the lab document for a batch

That is area percent, not mass percent. The trace cannot give you the second one.

area percent is relative to what the detector saw and nothing else

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

What does the wiki page on this say — genuinely asking, not deflecting?

That comparison is between two different products at two different concentrations, which is where the confusion is coming from.

Did you run a blank between injections?

Can you post the trace with the axes labelled?

research-use-only means not approved for human use, and here that covers everything

What week are you in?

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.

short peptides are cheap, which cuts both ways

axis labels or the trace is decoration

Not quite. Two labs with different gradients can resolve a close-eluting impurity differently and both be reporting honestly.

integration decisions move the number more than the sample does

Did you ask for the batch-specific document, or is this the catalogue one?

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

The online consultation asked me three questions, none of them about my history. I did not go ahead.

Correcting myself upthread: I said the gradient was linear and looking again it has a hold in the middle.

canada_coverage is right — the integration choice is a decision and it should be stated alongside the result.

the label on a compounded vial is a legal document, read it

LC-MS for identity, UV for relative quantity

Agreed. And the corollary is that the method line on a certificate is not decoration, it is the number’s provenance.

LC-MS for identity, UV for relative quantity

Not convinced by that integration. Dropping the baseline there absorbs part of the shoulder into the main peak.

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.

a shoulder is not an impurity until you can resolve it

the injection is easier than you are imagining

post the whole document, not the headline number

write the concentration on the vial, you will thank yourself

search first, but a repeat question is not a crime

Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.

214nm sees the peptide bond, 280nm sees the aromatics

Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.

Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.